Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan Extension in PAH
NCT02112487Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jun 2014; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02112487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112487.